Organizational changes to support development of retina programs at Ocular Therapeutix
Click Here to Manage Email Alerts
Ocular Therapeutix is making changes to its senior leadership team, according to a press release.
Peter K. Kaiser, MD, will join the company in the newly created role of chief medical advisor, retina. He will be tasked with advising on clinical development strategies for the company’s retina programs, including OTX-TKI, which is in phase 1 development for the treatment of wet age-related macular degeneration and other retinal diseases. He also will continue to serve as Chaney Family Endowed Chair in Ophthalmology Research and professor of ophthalmology at the Cleveland Clinic Lerner College of Medicine and Cole Eye Institute.
“The company’s lead program, OTX-TKI, has already demonstrated compelling results with a promising safety profile, a preliminary signal of biological activity, and durability that could change the standard of care for patients with wet AMD,” Kaiser said in the release. “I believe the same potential exists for application of the company’s hydrogel technology to other modalities like gene therapy and products used to treat a wide variety of retinal diseases.”
Additionally, Ocular Therapeutix’s current senior vice president of clinical development, Rabia Gurses Ozden, MD, will become chief medical officer on July 1, and current chief medical officer, president of ophthalmology, Michael Goldstein, MD, will shift to a part-time consulting position as chief strategy advisor.
“I am thrilled to be expanding our development capabilities with the addition of Dr. Kaiser as we advance our portfolio of innovative ophthalmic therapies for both front and back of the eye diseases,” Antony Mattessich, president and CEO of Ocular Therapeutix, said in the release. “Having someone of Dr. Kaiser’s caliber contributing to the great work we are already doing on the retina programs is extremely exciting. His extensive knowledge and experience should have an immediate impact as we finalize plans to advance OTX-TKI into phase 2 clinical development. We are developing this product candidate to set the standard of care for durability in the treatment of wet AMD.”
Read more about
Click Here to Manage Email Alerts